Ocular Therapeutix CEO Dugel sells $233,159 in shares

Pravin Dugel, the CEO of Ocular Therapeutix, Inc., sold 21,649 shares of the company's stock on August 24, 2026. The shares were sold at an average price of $10.77 each, with prices ranging from $10.64 to $10.90 per share. This transaction, a sell-to-cover, was necessary to meet tax obligations resulting from the vesting of restricted stock units on August 22, 2026.

The total value of the shares sold was $233,159. Dugel, who now holds 2,525,429 shares, made this sale pursuant to an automatic instruction established in February 2024. Following the sale, Dugel's spouse transferred 50,092 shares to an irrevocable trust for no consideration, with Dugel remaining as the sole beneficiary. Ocular Therapeutix is currently trading below its Fair Value, with analysts forecasting a potential increase in stock price between $18 and $34.

The company recently announced its intent to submit an NDA for AXPAXLI in Q4 of 2026, aiming to treat wet age-related macular degeneration. This move follows an agreement with the FDA concerning the data for the NDA. H.C. Wainwright raised its price target for Ocular Therapeutix to $25 and maintained a Buy rating, while Citizens upgraded its rating to Market Outperform with a price target of $34.

Options trading volume increased significantly, with 9,882 call contracts and only 12 put contracts, reflecting heightened market activity.